Biotech stock Merus NV (NASDAQ:MRUS) is up 3.4% at $44.40 at last glance, though pulling back a bit from its premarket surge, after Goldman Sachs initiated coverage with a "buy" rating. The firm cited potential growth from the company's cancer treatment. Today's pop has MRUS looking to snap an eight-day losing streak. The stock dropped below long-term support at the 200-day moving average during this most recent pullback, which ended today at $42. This level also coincides with MRUS' pre-bull gap level in A ...